Hyppää sisältöön
    • Suomeksi
    • In English
Trepo
  • Suomeksi
  • In English
  • Kirjaudu
Näytä viite 
  •   Trepo etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
  •   Trepo etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma

Korja, Miikka; Jokilammi, Anne; Salmi, Toivo T; Kalimo, Hannu; Pelliniemi, Tarja-Terttu; Isola, Jorma; Rantala, Immo; Haapasalo, Hannu; Finne, Jukka (2009)

 
Tweet refworks
 
Avaa tiedosto
absence_of_polysialylated_ncam_NCAM_2009.pdf (1.108Mt)
Lataukset: 



Korja, Miikka
Jokilammi, Anne
Salmi, Toivo T
Kalimo, Hannu
Pelliniemi, Tarja-Terttu
Isola, Jorma
Rantala, Immo
Haapasalo, Hannu
Finne, Jukka
2009

BMC Cancer 9
57
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.
doi:10.1186/1471-2407-9-57
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
http://urn.fi/urn:nbn:uta-3-556

Kuvaus

BioMed Central Open access
Tiivistelmä
Background

The expression of a neural crest stem cell marker, polysialic acid (polySia), and its main carrier, neural cell adhesion molecule (NCAM), have been detected in some malignant tumors with high metastatic activity and unfavorable prognosis, but the diagnostic and prognostic value of polySia-NCAM in neuroblastoma is unclear.

Methods

A tumor tissue microarray (TMA) of 36 paraffin-embedded neuroblastoma samples was utilized to detect polySia-NCAM expression with a polySia-binding fluorescent fusion protein, and polySia-NCAM expression was compared with clinical stage, age, MYCN amplification status, histology (INPC), and proliferation index (PI).

Results

PolySia-NCAM-positive neuroblastoma patients had more often metastases at diagnosis, and polySia-NCAM expression associated with advanced disease (P = 0.047). Most interestingly, absence of polySia-NCAM-expressing tumor cells in TMA samples, however, was a strong unfavorable prognostic factor for overall survival in advanced disease (P = 0.0004), especially when MYCN was not amplified. PolySia-NCAM-expressing bone marrow metastases were easily detected in smears, aspirates and biopsies.

Conclusion

PolySia-NCAM appears to be a new clinically significant molecular marker in neuroblastoma, hopefully with additional value in neuroblastoma risk stratification.
Kokoelmat
  • Artikkelit [6066]
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Yhteydenotto | Tietosuoja | Saavutettavuusseloste
 

 

Selaa kokoelmaa

TekijätNimekkeetTiedekunta (2019 -)Tiedekunta (- 2018)Tutkinto-ohjelmat ja opintosuunnatAvainsanatJulkaisuajatKokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Yhteydenotto | Tietosuoja | Saavutettavuusseloste